A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine

Applied Health Economics and Health Policy

Volumn 7, Issue 4, 2009, Pages 245-254

  Misurski, Derek ^a   Lage, Maureen J ^b   Fabunmi, Rosalind ^c   Boye, Kristina S ^a  

^a ELI LILLY AND COMPANY   (United States)

^b HealthMetrics Outcomes Research LLC   (United States)

^c AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; INSULIN GLARGINE; ORAL ANTIDIABETIC AGENT;

ADULT; ARTICLE; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; DRUG COST; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PROBABILITY; PUBLIC HEALTH; TREATMENT RESPONSE;

COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; HEALTH CARE COSTS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MIDDLE AGED; PEPTIDES; VENOMS;

EID: 73549100870     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.2165/11318730-000000000-00000     Document Type: Article

References (42)

1. American Diabetes Association. Economic costs of diabetes in the US in 2007 [published erratum appears in Diabetes Care 2008; 31 (6): 1271]. Diabetes Care 2008; 31: 596-615
2. American Diabetes Association. Standards of medical care in diabetes: 2008. Diabetes Care 2008; 31 Suppl. 1: S12-54
3. Edwards KL, Alvarez C, Irons BK, et al. Third-line agent selection for patients with type 2 diabetes mellitus uncontrolled with sulfonylureas and metformin. Pharmacotherapy 2008; 28 (4): 506-521
4. Gerich JE. Insulin glargine: long acting basal insulin analog for improved metabolic control. Curr Med Res Opin 2004; 20: 31-37
5. BNET. Aventis Pharmaceuticals' LANTUS- (insulin glargine [rDNA origin] injection) approved by FDA for treatment of diabetes. Market Wire [online]. Available from URL: http://findarticles.com/p/articles/mi-pwwi/is-200004/ai- mark09008855 [Accessed 2008 Sep 23]
6. US Food and Drug Administration. CDER drug and biologic approvals for calendar year 2005 [online]. Available from URL: http://www.fda.gov/cder/rdmt/ InternetNDA 05.htm [Accessed 2008 Sep 23]
7. Barclay L. Exenatide approved for type 2 diabetes: an expert interview with John B. Buse. Medscape Today [online]. Available fromURL: http://www.medscape.com/viewarticle/ 504227 [Accessed 2008 Sep 23]
8. Nielsen LL, Okerson T, Holcombe J, et al. Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes. J Diab Sci Tech 2008; 2: 255-260
9. Stonehouse AH, Maggs DG. Emerging therapies for type 2 diabetes. Curr Drug Ther 2007; 2: 151-160
10. Degn KB, Brock B, Juhl CB, et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucosedependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004; 53: 2397-2403
11. Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon- like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin EndocrinolMetab 2002; 87: 1239-1246
12. Cvetkovic RS, Plosker GL. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea). Drugs 2007; 67: 935-954
13. Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005; 62: 173-181
14. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Annals Int Med 2005; 143: 559-569
15. Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007; 29: 2333-2348
16. Yu AP, Wu EQ, Birnbaum HG, et al. Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data. Curr Med Res Opin 2007; 23 (9): 2157-2169
17. Bray GA, Bellanger T. Epidemiology, trends, and morbidities of obesity and the metabolic syndrome. Endocrine 2006; 29: 109-117
18. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289: 76-79
19. Maggio CA, Pi-Sunyer FX. Obesity and type 2 diabetes. Endocrinol Metab Clin North Am 2003; 32: 805-822
20. Williamson DF, Thompson TJ, Thun M, et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000; 23: 1499-1504
21. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005; 143 (8): 559-569
22. Miller DR, Gardner JA, Hendricks AM, et al. Health care resource utilization and expenditures associated with the use of insulin glargine. Clin Ther 2007; 29 (3): 478-487
23. Warren E, Weatherley-Jones E, Chilcott J, et al. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technol Assess 2004 Nov; 8 (45): 1-57
24. Suntsov YI, Dedov II, Komarova VP, et al. Pharmacoeconomic aspects of use of insulin glargine in treatment of diabetes mellitus type 2 (dm t2) in Russia [abstract]. Value Health 2004; 7: 738
25. Goodall G, Jendle JH, Valentine WJ, et al. Biphasic insulin aspart 70/30 vs insulin glargine in insulin naive type 2 diabetes patients: modelling the long-term health economic implications in a Swedish setting. Int J Clin Pract 2008 Jun; 62 (6): 869-876
26. Janka HU, Högy B. Economic evaluation of the treatment of type 2 diabetes with insulin glargine based on the LAPTOP trial. Eur J Health Econ 2008 May; 9 (2): 165-170
27. Leichter S. Is the use of insulin analogues cost-effective? Adv Ther 2008 Jul-Aug; 25 (4): 285-299
28. Ray JA, Valentine WJ, Roze S, et al. Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs insulin glargine in the US. Diabetes Obes Metab 2007 Jan; 9 (1): 103-113 (Pubitemid 44921048)
29. Lechleitner M, Roden M, Haehling E, et al. Insulin glargine in combination with oral antidiabetic drugs as a costequivalent alternative to conventional insulin therapy in type 2 diabetes mellitus. Wien Klin Wochenschr 2005 Sep; 117 (17): 593-598
30. Valentine WJ, Palmer AJ, Lammert M, et al. Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting. Curr Med Res Opin 2005 Dec; 21 (12): 2063-2071
31. Wu EQ, Birnbaum HG, Zhang HF, et al. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies. J Manag Care Pharm 2007; 13: 561-569
32. Pelletier EM, Smith PJ, Boye KS, et al. Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research. Appl Health Econ Health Policy 2008; 6 (2-3); 103-112
33. Finkelstein EA, Bray JW, Chen H, et al. Prevalence and costs of major depression among elderly claimants with diabetes. Diabetes Care 2003; 26: 415-420
34. D'Hoore W, Sicotte C, Tilquin C. Risk adjustment in outcome assessment: the Charlson comorbidity index. Methods Inf Med 1993; 32: 382-387
35. Duan N. Smearing estimate: a nonparametric retransformation method. J Am Stat Assoc 1983; 78 (383): 605-610
36. Diehr P, Yanez D, Ash A, et al. Methods for analyzing health care utilization and costs. Annu Rev Public Health 1999; 20: 125-144
37. Duan N, Manning WG, Morris CN, et al. A comparison of alternative models for the demand for medical care. J Bus Econ Stat 1983; 1: 115-126
38. Ray JA, Boye KS, Yurgin N, et al. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes. Curr Med Res Opin 2007 Mar; 23 (3): 609-622
39. Oglesby AK, Secnik K, Barron J, et al. The association between diabetes related medical costs and glycemic control: a retrospective analysis. Cost Eff Resour Alloc 2006; 4: 1
40. Shetty S, Secnik K, Oglesby AK. Relationship of glycemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes. J Manag Care Pharm 2005; 11 (7): 559-564
41. Ayanian JZ, Hauptman PJ, Guadagnoli E, et al. Knowledge and practices of generalist and specialist physicians regarding drug therapy for acute myocardial infarction. N Engl J Med 1994 Oct 27; 331 (17): 1136-1142
42. i3. Data assets: better data matters [online]. Available from URL: http://www.i3global.com/DataAssets/ [Accessed 2008 Sep 23]